newsfilter
← Latest News
Business Wire·

Janux Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

Continued clinical execution across TRACTr programs JANX007 and JANX008 JANX007 enrolling in Phase 1b Taxane-naïve patient population in metastatic castration-resistant prostate cancer (mCRPC) JANX008 enrolling